Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 2 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
Certain Clinical Factors Tied to Poor Response to Biologics for Psoriasis
MedPage Today· 2 days agoPrevious exposure to biologics, higher BMI, smoking all negatively linked to response
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 2 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 20 hours agoIn addition, immune system irregularities, higher diagnosis rates, increased focus on early...
Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of “Moderate Buy” by Analysts
ETF DAILY NEWS· 7 hours agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, Marketbeat Ratings ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 13 hours agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Study led by UChicago Medicine physician finds new | Newswise
Newswise· 3 days agoA medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings ...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 1 day agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
The Gut-Skin Axis May Be the Key to Healthy, Glowing Skin
First for Women via Yahoo News· 7 days agoThe easiest way to do so? Take a daily probiotic supplement, which has been linked to lower rates of...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 14 hours agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...